Characterization of mechanism involved in acquired resistance to sorafenib in a mouse renal cell cancer RenCa model.

about

Activation of ERK1/2 Causes Pazopanib Resistance via Downregulation of DUSP6 in Synovial Sarcoma Cells.Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells.

P2860

Q37723943-ACAE9E70-0FC9-422A-97FF-BFE9A9A4E5EA Q38817505-02802274-E653-45EF-99F6-78A76522CCD1

P2860

Characterization of mechanism involved in acquired resistance to sorafenib in a mouse renal cell cancer RenCa model.

Item

http://www.wikidata.org/entity/Q39041660

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Characterization of mechanism ...... renal cell cancer RenCa model.

@en

Characterization of mechanism ...... renal cell cancer RenCa model.

@nl

type

Item

label

Characterization of mechanism ...... renal cell cancer RenCa model.

@en

Characterization of mechanism ...... renal cell cancer RenCa model.

@nl

prefLabel

Characterization of mechanism ...... renal cell cancer RenCa model.

@en

Characterization of mechanism ...... renal cell cancer RenCa model.

@nl

P1476

Characterization of mechanism ...... renal cell cancer RenCa model.

@en

P2093

H Miyake

http://www.w3.org/2001/XMLSchema#string

K Harada

http://www.w3.org/2001/XMLSchema#string

M Fujisawa

http://www.w3.org/2001/XMLSchema#string

Y Kusuda

http://www.w3.org/2001/XMLSchema#string

P2860

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

Modes of resistance to anti-angiogenic therapy

Sorafenib in advanced clear-cell renal-cell carcinoma

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression.

Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling.

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma.

Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model.

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

P2888

s12094-013-1151-9

P304

801-806

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12094-013-1151-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-12-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24356934

http://www.w3.org/2001/XMLSchema#string

Characterization of mechanism involved in acquired resistance to sorafenib in a mouse renal cell cancer RenCa model.

about

P2860

P2860

Characterization of mechanism involved in acquired resistance to sorafenib in a mouse renal cell cancer RenCa model.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698